Diverse Manifestations of COVID-19: Some Suggested Mechanisms
Abstract
:1. Introduction
2. Probable Explanations for Why SARS-CoV-2 Positive Individuals Remain Asymptomatic or Have Mild Symptoms
2.1. COVID-19 Immunity from Other Unrelated Vaccinations
2.2. Memory T Cell-Mediated Immunity
2.3. ACE2 Receptors
2.4. Deficiency in Type I and Type III Interferons
2.5. Cross-Reacting Antibodies to Other Coronaviruses
2.6. Differences Due to Age
3. Discussion and Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Liu, D.X.; Liang, J.Q.; Fung, T.S. Human Coronavirus-229E, -OC43, -NL63, and -HKU1 Reference Module in Life. Science 2020, 90, 8478–8486. [Google Scholar] [CrossRef]
- Mercatelli, D.; Giorgi, F.M. Geographic and Genomic Distribution of SARS-CoV-2 Mutations. Front. Microbiol. 2020, 11, 1800. [Google Scholar] [CrossRef]
- CSSE (Center for Systems Science and Engineering). Tracking COVID-19. 2021. Available online: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6 (accessed on 3 September 2021).
- Institute for Health Metrics and Evaluation (IHME). Estimation of Excess Mortality Due to COVID-19. 2021. Available online: http://www.healthdata.org/special-analysis/estimation-excess-mortality-due-covid-19-and-scalars-reported-covid-19-deaths (accessed on 4 September 2021).
- Couzin-Frankel, J. From ‘Brain Fog’ to Heart Damage, COVID-19′s Lingering Problems Alarm Scientists. 2020. Available online: https://www.sciencemag.org/news/2020/07/brain-fog-heart-damage-covid-19-s-lingering-problems-alarm-scientists (accessed on 23 December 2020).
- CDC (Center for Disease Control). Symptoms of Corona Virus. 2020. Available online: https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html (accessed on 23 December 2020).
- WHO (World Health Organization). Coronavirus. 2020. Available online: https://www.who.int/health-topics/coronavirus#tab=tab_3 (accessed on 23 December 2020).
- CDC (Center for Disease Control). Coronavirus Disease 2019 (COVID-19): People with Certain Medical Condition. 2020. Available online: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html?CDC_AA_refVal=https%3A%2F%2Fwww.cdc.gov%2Fcoronavirus%2F2019-ncov%2Fneed-extra-precautions%2Fgroups-at-higher-risk.html (accessed on 14 January 2021).
- Faust, J.S.; Krumholz, H.M.; Du, C.; Mayes, K.D.; Lin, Z.; Gilman, C.; Walensky, R.P. All-Cause Excess Mortality and COVID-19–Related Mortality Among US Adults Aged 25–44 Years, March–July 2020. JAMA 2021, 325, 785–787. [Google Scholar] [CrossRef]
- Long, Q.; Tang, X.; Shi, Q.; Li, Q.; Deng, H.; Yuan, J.; Hu, J.; Xu, W.; Zhang, Y.; Lv, F.; et al. Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections. Nat. Med. 2020, 26, 1200–1204. Available online: https://0-www-nature-com.brum.beds.ac.uk/articles/s41591-020-0965-6 (accessed on 15 June 2021). [CrossRef] [PubMed]
- Cha, A.E. Forty Percent of People with Coronavirus Infections Have No Symptoms. Might They Be the Key to Ending the Pandemic? 2020. Available online: https://www.washingtonpost.com/health/2020/08/08/asymptomatic-coronavirus-covid/ (accessed on 29 December 2020).
- Cha, A.E. Many People with the Coronavirus don’t Show Symptoms. Researchers Want to Know Why. 2020. Available online: https://www.bostonglobe.com/2020/08/08/nation/many-people-with-coronavirus-dont-show-symptoms-researchers-want-know-why/ (accessed on 29 December 2020).
- Pattersson, H.; Manley, B.; Hernandez, S. Tracking Covid-19′s Global Spread. 2021. Available online: https://www.cnn.com/interactive/2020/health/coronavirus-maps-and-cases/ (accessed on 4 January 2021).
- Miller, A.; Reandelar, M.J.; Fasciglione, K.; Roumenova, V.; Li, Y.; Otazu, G.H. Correlation between universal BCG vaccination policy and reduced morbidity and mortality for COVID-19: An epidemiological study. MedRxiv 2020. [Google Scholar] [CrossRef] [Green Version]
- Mathurin, K.S.; Martens, G.; Kornfeld, H.; Welsh, R.M. CD4 T-Cell-Mediated Heterologous Immunity between Mycobacteria and Poxviruses. J. Virol. 2009, 83, 3528–3539. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zwerling, A.; Behr, M.A.; Verma, A.; Brewer, T.F.; Menzies, D.; Pai1, M. The BCG World Atlas: A Database of Global BCG Vaccination Policies and Practices. PLoS Med. 2011, 8, e1001012. [Google Scholar] [CrossRef] [Green Version]
- Keener, A.B.; Repurposed Remedy. A 100-Year-Old Weapon against TB Shows Early Promise Against Multiple Diseases. 2021. Available online: https://dokumen.pub/qdownload/june-5-2021-sciencenews.html (accessed on 14 July 2021).
- Escobar, L.E.; Molina-Cruz, A.; Barillas-Mury, C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). Proc. Natl. Acad. Sci. USA 2020, 117, 17720–17726. [Google Scholar] [CrossRef]
- Fidel, P.L.; Noverrb, M.C. Could an Unrelated Live Attenuated Vaccine Serve as a Preventive Measure to Dampen Septic Inflammation Associated with COVID-19 Infection? mBio 2020, 11, e00907–e00920. [Google Scholar] [CrossRef]
- Giamarellos-Bourboulis, E.J.; Tsilika, M.; Moorlag, S.; Antonakos, N.; Kotsaki, A.; Dominguez-Andres, J.; Kyriazopoulou, E.; Gkavogianni, M.-E.; Adami, M.-E.; Damoraki, G.; et al. Activate: Randomized Clinical Trial of BCG Vaccination against Infection in the Elderly. Cell 2020, 183, 315–323. [Google Scholar] [CrossRef]
- Rivas, M.N.; Ebinger, J.E.; Wu, M.; Sun, N.; Braun, J.; Sobani, K.; Van Eyk, J.E.; Cheng, S.; Arditi, M. BCG Vaccination History Associates with Decreased SARS-COV-2 Seroprevalence Across a Diverse Cohort of Health Care Workers. J. Clin. Investig. 2021, 131, e145157. [Google Scholar] [CrossRef]
- Marín-Hernandez, D.; Nixon, D.F.; Hupert, N. Anticipated reduction in COVID-19 mortality due to population-wide BCG vaccination: Evidence from Germany. Human Vacc. Immunother. 2021, 44, 1–3. [Google Scholar] [CrossRef]
- McLean, H.Q.; Fiebelkorn, A.P.; Temte, J.I.; Wallace, G.S. Prevention of Measles, Rubella, Congenital Rubella Syndrome, and Mumps. 2013. Available online: https://www.cdc.gov/mmwr/pdf/rr/rr6204.pdf (accessed on 13 March 2021).
- Lapid, N. Childhood Vaccine Linked to Less Severe COVID-19, Cigarette Smoke Raises Risk. 2020. Available online: https://www.reuters.com/article/us-health-coronavirus-science/childhood-vaccine-linked-to-less-severe-covid-19-cigarette-smoke-raises-risk-idUSKBN2802LP (accessed on 14 March 2021).
- Marakasova, E.; Baranova, A. MMR Vaccine and COVID-19: Measles Protein Homology May Contribute to Cross-Reactivity or to Complement Activation Protection. mBio 2021, 12, e03447–e20. [Google Scholar] [CrossRef]
- Gold, J.E.; Baumgartl, W.H.; Okyay, R.A.; Licht, W.E.; Fidel, P.L.; Noverr, M.C.; Tilley, L.P.; Hurley, D.J.; Rada, B.; Ashford, J.W. Analysis of Measles-Mumps-Rubella (MMR) Titers of Recovered COVID-19 Patients. mBio 2020, 11, e02628–e20. Available online: https://mbio.asm.org/content/11/6/e02628-20 (accessed on 15 June 2021). [CrossRef] [PubMed]
- Root-Bernstein, R. Possible Cross-Reactivity between SARS-CoV-2 Proteins, CRM197 and Proteins in Pneumococcal Vaccines May Protect Against Symptomatic SARS-CoV-2 Disease and Death. Vaccines 2020, 8, 559. [Google Scholar] [CrossRef]
- Comunale, B.A.; Engineer, L.; Jiang, Y.; Andrews, J.C.; Liu, Q.; Ji, L.; Yurkovich, J.T.; Comunale, R.A.; Xie, Q. Poliovirus Vaccination Induces a Humoral Immune Response that Cross Reacts with SARS-CoV-2. MedRxiv 2021. [Google Scholar] [CrossRef]
- Le Bert, N.; Tan, A.T.; Kunasegaran, K.; Tham, C.Y.L.; Hafezi, M.; Chia, A.; Chng, M.H.Y.; Lin, M.; Tan, N.; Linster, M.; et al. SARS-CoV-2-specific T cell immunity in cases of COVID-19 and SARS, and uninfected controls. Nature 2020, 584, 457–462. [Google Scholar] [CrossRef]
- Wang, Z.; Yang, X.; Zhong, J.; Zhou, Y.; Tang, Z.; Zhou, H.; He, J.; Mei, X.; Tang, Y.; Lin, B.; et al. Exposure to SARS-CoV-2 generates T-cell memory in the absence of a detectable viral infection. Nat. Commun. 2021, 12, 1724. [Google Scholar] [CrossRef]
- Wang, Z.; Yang, X.; Zhou, Y.; Sun, J.; Liu, X.; Zhang, J.; Mei, X.; Zhong, J.; Zhao, J.; Ran, P. COVID-19 severity correlates with weaker T-Cell immunity, hypercytokinemia, and lung epithelium injury. Am. J. Respir. Crit. Care Med. 2020, 202, 606–610. [Google Scholar] [CrossRef]
- Ni, W.; Yang, X.; Yang, D.; Bao, J.; Li, R.; Xiao, Y.; Hou, C.; Wang, H.; Liu, J.; Yang, D.; et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care 2020, 24, 422. [Google Scholar] [CrossRef]
- Sriram, K.; Insel, P.; Loomba, R. What is the ACE2 receptor, how is it connected to coronavirus and why might it be key to treating COVID-19? The Experts Explain. 2020. Available online: https://theconversation.com/what-is-the-ace2-receptor-how-is-it-connected-to-coronavirus-and-why-might-it-be-key-to-treating-covid-19-the-experts-explain-136928 (accessed on 28 June 2021).
- Gurley, S.B.; Coffman, T.M. Angiotensin-converting enzyme 2 gene targeting studies in mice: Mixed messages. Exp. Physiol. 2008, 93, 538–542. [Google Scholar] [CrossRef] [PubMed]
- Santos, S.H.S.; Andrade, J.M.O. Angiotensin 1–7: A peptide for preventing and treating metabolic syndrome. Peptides 2014, 59, 34–41. [Google Scholar] [CrossRef]
- Sriram, K.; Insel, P.A. A hypothesis for pathobiology and treatment of COVID-19: The centrality of ACE1/ACE2 imbalance. Brit. Pharm. Soc. 2020, 177, 4825–4844. [Google Scholar] [CrossRef]
- Chappell, M.C. Biochemical evaluation of the renin-angiotensin system: The good, bad, and absolute? Am. J. Physiol. 2016, 310, H137–H152. [Google Scholar] [CrossRef] [Green Version]
- Benter, I.F.; Yousif, M.H.; Dhaunsi, G.S.; Kaur, J.; Chappell, M.C.; Diz, D.I. Angiotensin-(1-7) prevents activation of NADPH oxidase and renal vascular dysfunction in diabetic hypertensive rats. Am. J. Nephrol. 2008, 28, 25–33. [Google Scholar] [CrossRef]
- El-Hashim, A.Z.; Renno, W.M.; Raghupathy, R.; Abduo, H.T.; Akhtar, S.; Benter, I.F. Angiotensin-(1-7) inhibits allergic inflammation, via the MAS1 receptor, through suppression of ERK1/2- and NF-κB-dependent pathways. Brit. J. Pharmacol. 2012, 166, 1964–1976. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Santos, R.A.S.; Sampaio, W.O.; Alzamora, A.C.; Motta-Santos, D.; Alenina, N.; Bader, M.; Campagnole-Santos, M.J. The ACE2/Angiotensin-(1-7)/MAS Axis of the Renin-Angiotensin System: Focus on Angiotensin-(1-7). Physiol. Rev. 2018, 1, 505–553. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Hoffmann, M.; Kleine-Weber, H.; Schroeder, S.; Krüger, N.; Herrler, T.; Erichsen, S.; Schiergens, T.S.; Herrler, G.; Wu, N.; Nitsche, A.; et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell 2020, 181, 271–280.e8. [Google Scholar] [CrossRef] [PubMed]
- Sungnak, W.; Huang, N.; Becavin, C.; Berg, M.; Queen, R.; Litvinukova, M.; Talavera-Lopez, C.; Maatz, H.; Reichart, D.; Sampaziotis, F.; et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020, 26, 681–687. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Qiao, Y.; Wang, X.-M.; Mannan, R.; Pitchiaya, S.; Zhang, Y.; Wotring, J.W.; Xiao, L.; Robinson, D.R.; Wu, Y.-M.; Tien, J.C.-Y.; et al. Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2. Proc. Nat. Acad. Sci. USA 2021, 118, e2021450118. [Google Scholar] [CrossRef] [PubMed]
- Baughn, L.B.; Sharma, N.; Elhaik, E.; Sekulic, A.; Bryce, A.H.; Fonseca, R. Targeting TMPRSS2 in SARS-CoV-2 Infection. Mayo Clin. Proc. 2020, 95, 1989–1999. [Google Scholar] [CrossRef] [PubMed]
- Meffre, E.; Iwasaki, A. Interferon deficiency can lead to severe COVID. Nature 2020, 587, 374–376. [Google Scholar] [CrossRef] [PubMed]
- Sa Ribero, M.; Jouvenet, N.; Dreux, M.; Nisole, S. Interplay between SARS-CoV-2 and the type I interferon response. PLoS Pathog. 2020, 16, e1008737. [Google Scholar] [CrossRef]
- Zhang, Q.; Bastard, P.; Liu, Z.; Le Pen, J.; Moncada-Velez, M.; Chen, J.; Ogishi, M.; Sabli, I.K.D.; Hodeib, S.; Korol, C.; et al. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. Science 2020, 370, 1396–1400. [Google Scholar] [CrossRef] [PubMed]
- Bastard, P.; Rosen, L.B.; Zhang, Q.; Michailidis, E.; Hoffmann, H.H.; Zhang, Y. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science 2020, 370, eabd4585. [Google Scholar] [CrossRef] [PubMed]
- Davoudi-Monfared, E.; Rahmani, H.; Khalili, H.; Hajiabdolbaghi, M.; Salehi, M.; Abbasian, L.; Kazemzadeh, H.; Yekaninejad, M.S. A randomized clinical trial of the efficacy and safety of interferon β-1a in treatment of severe COVID-19. Antimicrob. Agents Chemother. 2020, 64, e01061–e20. [Google Scholar] [CrossRef]
- Qiang, Z.; Chen, V.; Shannon, C.P.; Wei, X.; Xiany, X.; Wang, X.; Wang, Z.; Tebbutt, S.J.; Kollmann, T.R.; Fish, E.N. Interferon -α2b Treatment for COVID-19. Front. Immunol. 2020, 11, 1061. Available online: https://www.frontiersin.org/articles/10.3389/fimmu.2020.01061/full (accessed on 4 May 2021).
- Jafarzadeh, A.; Nemati, M.; Saha, B.; Bansode, Y.D.; Jafarzadeh, S. Protective Potentials of Type III Interferons in COVID-19 Patients: Lessons from Differential Properties of Type I- and III Interferons. Viral. Immunol. 2021, 34, 307–320. [Google Scholar] [CrossRef] [PubMed]
- Kim, Y.M.; Shin, E.C. Type I and III interferon responses in SARS-CoV-2 infection. Exp. Mol. Med. 2021, 53, 750–760. [Google Scholar] [CrossRef]
- Kim, M.-H.; Salloum, S.; Wang, J.Y.; Ping, W.L.; Regan, J.; Lefteri, K.; Manickas-Hill, Z.; Gao, C.; Li, J.Z.; I Sadreyev, R.; et al. Type I, II, and III interferon signatures correspond to COVID-19 disease severity. J. Infect. Dis. 2021, 224, 777–782. [Google Scholar] [CrossRef]
- Broggi, A.; Ghosh, S.; Sposito, B.; Spreafico, R.; Balzarini, F.; Cascio, A.L.; Clementi, N.; De Santis, M.; Mancini, N.; Granucci, F.; et al. Type III interferons disrupt the lung epithelial barrier upon viral recognition. Science 2020, 369, 706–712. [Google Scholar] [CrossRef]
- Fliesler, N. Type III Interferon in COVID-19: Protective or Harmful? 2020. Available online: https://answers.childrenshospital.org/interferon-covid-19/ (accessed on 5 September 2021).
- Sriskandan, K.; Garner, P.; Watkinson, J.; Pettingale, K.W.; Brinkley, D.; Calman, F.M.; Tee, D.E. A toxicity study of recombinant interferon-gamma given by intravenous infusion to patients with advanced cancer. Cancer Chemother Pharm. 1986, 18, 63–68. [Google Scholar] [CrossRef]
- Ng, K.W.; Faulkner, N.; Cornish, G.H.; Rosa, A.; Harvey, R.; Hussain, S. Preexisting and de novo humoral immunity to SARS-CoV-2 in humans. Science 2020, 370, 1339–1343. [Google Scholar] [CrossRef]
- Tso, F.Y.; Lindenage, S.J.; Pena, P.B.; Clegg, A.A.; Ngowi, J.R.; Mwaiselage, J.; Ngalamika, O.; Julius, P.; West, J.T.; Wood, C. High prevalenace of pre-existing serological cross-reactivity against severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in sub-Sharan Africa. Int. J. Infect. Dis. 2021, 102, 577–583. [Google Scholar] [CrossRef] [PubMed]
- Shibata, S.; Ishiguro, T.; Kobayashi, Y.; Koike, M.; Numano, T.; Shimizu, Y.; Taksyanagi, N. High incidence of false-positive results of IgG antibody against SARS-CoV-2 with rapid immunochromatographic antibody test due to human common cold coronavirus infection. Respir. Med. Case Rep. 2020, 31, 101180. [Google Scholar] [CrossRef]
- Girona-Alarcon, M.; Bobillo-Perez, S.; Sole-Ribalta, A.; Hernandez, L.; Guitart, C.; Suarez, R.; Balaguer, M.; Francisco-Jose, C.; Jordan, I. The different manifestations of COVID-19 in adults and children: A cohort study in an intensive care unit. BMC Infect. Dis. 2021, 21, 87. [Google Scholar] [CrossRef] [PubMed]
- Kloc, M.; Ghobrial, R.M.; Kuchar, E.; Lewicki, S.; Kubiak, J.Z. Development of child immunity in the context of COVID-19 pandemic. Clin. Immunol. 2020, 217, 108510. [Google Scholar] [CrossRef] [PubMed]
- CDC (Center for Disease Control). Polio Vaccination: What Everyone Should Know. 2018. Available online: https://www.cdc.gov/vaccines/vpd/polio/public/index.html (accessed on 24 December 2020).
- CDC (Center for Disease Control). Pneumococcal Vaccination: What Everyone Should Know. 2020. Available online: https://www.cdc.gov/vaccines/vpd/pneumo/public/index.html (accessed on 27 December 2020).
- Lewnard, J.A.; Bruxvoort, K.J.; Fischer, H.; Hong, V.X.; Grant, L.R.; Jodar, L.; Gessner, B.D.; Tartof, S.Y. Prevention of COVID-19 among older adults receiving pneumococcal conjugate vaccine suggests interaction between Streptococcus pneumoniae and SARS-CoV-2 in the respiratory tract. J. Infect. Dis. 2021, 128, 156. [Google Scholar] [CrossRef]
- WHO. The Effects of Virus Variants on COVID-19 Vaccines. 2021. Available online: https://www.who.int/news-room/feature-stories/detail/the-effects-of-virus-variants-on-covid-19-vaccines?gclid=Cj0KCQjw-NaJBhDsARIsAAja6dOyeZWwc31zI3NLSaIkNYJW51JTwwV20V3E8KRseBFHx0BjbjWW7aMaAgf-EALw_wcB (accessed on 6 September 2021).
- CDC (Center for Disease Control). Smallpox. 2017. Available online: https://www.cdc.gov/smallpox/ (accessed on 1 June 2021).
- History of Polio. 2018. Available online: https://www.historyofvaccines.org/timeline/polio (accessed on 10 June 2021).
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Zaman, M.S.; Sizemore, R.C. Diverse Manifestations of COVID-19: Some Suggested Mechanisms. Int. J. Environ. Res. Public Health 2021, 18, 9785. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18189785
Zaman MS, Sizemore RC. Diverse Manifestations of COVID-19: Some Suggested Mechanisms. International Journal of Environmental Research and Public Health. 2021; 18(18):9785. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18189785
Chicago/Turabian StyleZaman, Md S., and Robert C. Sizemore. 2021. "Diverse Manifestations of COVID-19: Some Suggested Mechanisms" International Journal of Environmental Research and Public Health 18, no. 18: 9785. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18189785